About 50% of all patients treated with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) achieve complete remission, and about one third experience longterm disease-free survival and cure. Attempts to improve results by modifications of CHOP using escalated doses, additional drugs or the alternative use of putatively non-cross resistant chemotherapy regimens failed in randomised trials...
Financed by the National Centre for Research and Development under grant No. SP/I/1/77065/10 by the strategic scientific research and experimental development program:
SYNAT - “Interdisciplinary System for Interactive Scientific and Scientific-Technical Information”.